6 key facts about JAK inhibitors

The agents are increasingly used in rheumatology

Janus kinase inhibitors, known as JAK inhibitors or jakinibs, are increasingly used in rheumatology.

Jak inhibitors

In Australia, two such drugs are PBS listed:  tofacitinib (Pfizer, Xeljanz) and baricitinib (Eli Lilly, Olumiant).

Both are indicated for severe active rheumatoid arthritis and must be prescribed by a suitable specialist.

But what are these drugs, how do they work, and what adverse effects can they cause?

JAK inhibitors